Which has preferable valuation & earnings, DVA or ALGN?

DaVita has higher revenue and earnings than Align Technology. DaVita is trading at a lower price-to-earnings ratio than Align Technology, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DaVita $13.64B 1.13 $746.80M $10.78 22.26 Align Technology $4.03B 3.00 $410.35M $5.75 29.42

Is DVA or ALGN more profitable?

Align Technology has a net margin of 9.99% compared to DaVita's net margin of 5.65%. Align Technology's return on equity of 15.86% beat DaVita's return on equity. Company Net Margins Return on Equity Return on Assets DaVita 5.65% -270.37% 4.87% Align Technology 9.99% 15.86% 10.32%

Does the media prefer DVA or ALGN?

In the previous week, Align Technology had 15 more articles in the media than DaVita. MarketBeat recorded 29 mentions for Align Technology and 14 mentions for DaVita. DaVita's average media sentiment score of 1.08 beat Align Technology's score of 0.87 indicating that DaVita is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DaVita 10 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Align Technology 11 Very Positive mention(s) 4 Positive mention(s) 9 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, DXCM or DVA?

DexCom has higher earnings, but lower revenue than DaVita. DaVita is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DexCom $4.66B 6.91 $836.30M $2.53 32.98 DaVita $13.64B 1.13 $746.80M $10.78 22.26

Is DXCM or DVA more profitable?

DexCom has a net margin of 20.12% compared to DaVita's net margin of 5.65%. DexCom's return on equity of 35.34% beat DaVita's return on equity. Company Net Margins Return on Equity Return on Assets DexCom 20.12% 35.34% 14.55% DaVita 5.65% -270.37% 4.87%

Does the media prefer DXCM or DVA?

In the previous week, DexCom had 40 more articles in the media than DaVita. MarketBeat recorded 54 mentions for DexCom and 14 mentions for DaVita. DaVita's average media sentiment score of 1.08 beat DexCom's score of 0.94 indicating that DaVita is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DexCom 25 Very Positive mention(s) 4 Positive mention(s) 16 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive DaVita 10 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, DVA or HQY?

DaVita has higher revenue and earnings than HealthEquity. DaVita is trading at a lower price-to-earnings ratio than HealthEquity, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DaVita $13.64B 1.13 $746.80M $10.78 22.26 HealthEquity $1.31B 6.40 $215.20M $2.67 37.68

Is DVA or HQY more profitable?

HealthEquity has a net margin of 17.25% compared to DaVita's net margin of 5.65%. HealthEquity's return on equity of 14.75% beat DaVita's return on equity. Company Net Margins Return on Equity Return on Assets DaVita 5.65% -270.37% 4.87% HealthEquity 17.25% 14.75% 9.22%

Does the media refer more to DVA or HQY?

In the previous week, DaVita had 4 more articles in the media than HealthEquity. MarketBeat recorded 14 mentions for DaVita and 10 mentions for HealthEquity. HealthEquity's average media sentiment score of 1.49 beat DaVita's score of 1.08 indicating that HealthEquity is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DaVita 10 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive HealthEquity 10 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, DVA or MMSI?

DaVita has higher revenue and earnings than Merit Medical Systems. DaVita is trading at a lower price-to-earnings ratio than Merit Medical Systems, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DaVita $13.64B 1.13 $746.80M $10.78 22.26 Merit Medical Systems $1.52B 3.35 $128.49M $2.31 36.80

Does the media refer more to DVA or MMSI?

In the previous week, Merit Medical Systems had 19 more articles in the media than DaVita. MarketBeat recorded 33 mentions for Merit Medical Systems and 14 mentions for DaVita. Merit Medical Systems' average media sentiment score of 1.24 beat DaVita's score of 1.08 indicating that Merit Medical Systems is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DaVita 10 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Merit Medical Systems 19 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, CAH or DVA?

Cardinal Health has higher revenue and earnings than DaVita. DaVita is trading at a lower price-to-earnings ratio than Cardinal Health, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cardinal Health $250.74B 0.22 $1.56B $6.54 35.20 DaVita $13.64B 1.13 $746.80M $10.78 22.26

Does the media prefer CAH or DVA?

In the previous week, Cardinal Health had 7 more articles in the media than DaVita. MarketBeat recorded 21 mentions for Cardinal Health and 14 mentions for DaVita. Cardinal Health's average media sentiment score of 1.35 beat DaVita's score of 1.08 indicating that Cardinal Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cardinal Health 19 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive DaVita 10 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

DaVita (DVA) Competitors

$240.00 +1.14 (+0.48%)

Closing price 07/31/2026 03:59 PM Eastern

Extended Trading

$239.60 -0.39 (-0.16%)

As of 07/31/2026 07:34 PM Eastern

Compare

DVA vs. ALGN, DXCM, HQY, MMSI, and CAH

Should you buy DaVita stock or one of its competitors? MarketBeat compares DaVita with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with DaVita include Align Technology (ALGN), DexCom (DXCM), HealthEquity (HQY), Merit Medical Systems (MMSI), and Cardinal Health (CAH).

How does DaVita compare to Align Technology?

DaVita (NYSE:DVA) and Align Technology (NASDAQ:ALGN) are both large-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, valuation, earnings, analyst recommendations, media sentiment, profitability, institutional ownership and risk.

DaVita currently has a consensus target price of $216.50, indicating a potential downside of 9.79%. Align Technology has a consensus target price of $206.36, indicating a potential upside of 21.99%. Given Align Technology's stronger consensus rating and higher probable upside, analysts plainly believe Align Technology is more favorable than DaVita.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DaVita	1 Sell rating(s)	5 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.13
Align Technology	0 Sell rating(s)	6 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.67

DaVita has a beta of 0.88, meaning that its share price is 12% less volatile than the broader market. Comparatively, Align Technology has a beta of 1.67, meaning that its share price is 67% more volatile than the broader market.

90.1% of DaVita shares are held by institutional investors. Comparatively, 88.4% of Align Technology shares are held by institutional investors. 1.9% of DaVita shares are held by company insiders. Comparatively, 0.8% of Align Technology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Align Technology has a net margin of 9.99% compared to DaVita's net margin of 5.65%. Align Technology's return on equity of 15.86% beat DaVita's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DaVita	5.65%	-270.37%	4.87%
Align Technology	9.99%	15.86%	10.32%

In the previous week, Align Technology had 15 more articles in the media than DaVita. MarketBeat recorded 29 mentions for Align Technology and 14 mentions for DaVita. DaVita's average media sentiment score of 1.08 beat Align Technology's score of 0.87 indicating that DaVita is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DaVita	10 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Align Technology	11 Very Positive mention(s)	4 Positive mention(s)	9 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive

DaVita has higher revenue and earnings than Align Technology. DaVita is trading at a lower price-to-earnings ratio than Align Technology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DaVita	$13.64B	1.13	$746.80M	$10.78	22.26
Align Technology	$4.03B	3.00	$410.35M	$5.75	29.42

Summary

Align Technology beats DaVita on 11 of the 17 factors compared between the two stocks.

How does DaVita compare to DexCom?

DexCom (NASDAQ:DXCM) and DaVita (NYSE:DVA) are both large-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, earnings, risk, dividends, media sentiment, valuation, analyst recommendations and profitability.

DexCom has higher earnings, but lower revenue than DaVita. DaVita is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DexCom	$4.66B	6.91	$836.30M	$2.53	32.98
DaVita	$13.64B	1.13	$746.80M	$10.78	22.26

In the previous week, DexCom had 40 more articles in the media than DaVita. MarketBeat recorded 54 mentions for DexCom and 14 mentions for DaVita. DaVita's average media sentiment score of 1.08 beat DexCom's score of 0.94 indicating that DaVita is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DexCom	25 Very Positive mention(s)	4 Positive mention(s)	16 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
DaVita	10 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

DexCom has a net margin of 20.12% compared to DaVita's net margin of 5.65%. DexCom's return on equity of 35.34% beat DaVita's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DexCom	20.12%	35.34%	14.55%
DaVita	5.65%	-270.37%	4.87%

DexCom has a beta of 1.45, suggesting that its stock price is 45% more volatile than the broader market. Comparatively, DaVita has a beta of 0.88, suggesting that its stock price is 12% less volatile than the broader market.

DexCom currently has a consensus target price of $88.13, indicating a potential upside of 5.60%. DaVita has a consensus target price of $216.50, indicating a potential downside of 9.79%. Given DexCom's stronger consensus rating and higher possible upside, analysts clearly believe DexCom is more favorable than DaVita.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DexCom	1 Sell rating(s)	3 Hold rating(s)	21 Buy rating(s)	2 Strong Buy rating(s)	2.89
DaVita	1 Sell rating(s)	5 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.13

97.8% of DexCom shares are held by institutional investors. Comparatively, 90.1% of DaVita shares are held by institutional investors. 0.3% of DexCom shares are held by insiders. Comparatively, 1.9% of DaVita shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

DexCom beats DaVita on 13 of the 17 factors compared between the two stocks.

How does DaVita compare to HealthEquity?

DaVita (NYSE:DVA) and HealthEquity (NASDAQ:HQY) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, analyst recommendations, profitability, dividends and earnings.

DaVita has higher revenue and earnings than HealthEquity. DaVita is trading at a lower price-to-earnings ratio than HealthEquity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DaVita	$13.64B	1.13	$746.80M	$10.78	22.26
HealthEquity	$1.31B	6.40	$215.20M	$2.67	37.68

In the previous week, DaVita had 4 more articles in the media than HealthEquity. MarketBeat recorded 14 mentions for DaVita and 10 mentions for HealthEquity. HealthEquity's average media sentiment score of 1.49 beat DaVita's score of 1.08 indicating that HealthEquity is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DaVita	10 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
HealthEquity	10 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

90.1% of DaVita shares are held by institutional investors. Comparatively, 99.6% of HealthEquity shares are held by institutional investors. 1.9% of DaVita shares are held by company insiders. Comparatively, 1.6% of HealthEquity shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

DaVita has a beta of 0.88, suggesting that its share price is 12% less volatile than the broader market. Comparatively, HealthEquity has a beta of 0.21, suggesting that its share price is 79% less volatile than the broader market.

HealthEquity has a net margin of 17.25% compared to DaVita's net margin of 5.65%. HealthEquity's return on equity of 14.75% beat DaVita's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DaVita	5.65%	-270.37%	4.87%
HealthEquity	17.25%	14.75%	9.22%

DaVita presently has a consensus target price of $216.50, suggesting a potential downside of 9.79%. HealthEquity has a consensus target price of $110.93, suggesting a potential upside of 10.26%. Given HealthEquity's stronger consensus rating and higher probable upside, analysts clearly believe HealthEquity is more favorable than DaVita.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DaVita	1 Sell rating(s)	5 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.13
HealthEquity	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77

Summary

HealthEquity beats DaVita on 10 of the 16 factors compared between the two stocks.

How does DaVita compare to Merit Medical Systems?

DaVita (NYSE:DVA) and Merit Medical Systems (NASDAQ:MMSI) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, dividends, valuation, earnings, profitability, risk, institutional ownership and media sentiment.

Merit Medical Systems has a net margin of 9.22% compared to DaVita's net margin of 5.65%. Merit Medical Systems' return on equity of 13.97% beat DaVita's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DaVita	5.65%	-270.37%	4.87%
Merit Medical Systems	9.22%	13.97%	8.24%

DaVita has a beta of 0.88, meaning that its stock price is 12% less volatile than the broader market. Comparatively, Merit Medical Systems has a beta of 0.52, meaning that its stock price is 48% less volatile than the broader market.

DaVita presently has a consensus target price of $216.50, suggesting a potential downside of 9.79%. Merit Medical Systems has a consensus target price of $100.30, suggesting a potential upside of 17.99%. Given Merit Medical Systems' stronger consensus rating and higher probable upside, analysts plainly believe Merit Medical Systems is more favorable than DaVita.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DaVita	1 Sell rating(s)	5 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.13
Merit Medical Systems	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

In the previous week, Merit Medical Systems had 19 more articles in the media than DaVita. MarketBeat recorded 33 mentions for Merit Medical Systems and 14 mentions for DaVita. Merit Medical Systems' average media sentiment score of 1.24 beat DaVita's score of 1.08 indicating that Merit Medical Systems is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DaVita	10 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Merit Medical Systems	19 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

90.1% of DaVita shares are owned by institutional investors. Comparatively, 99.7% of Merit Medical Systems shares are owned by institutional investors. 1.9% of DaVita shares are owned by insiders. Comparatively, 0.7% of Merit Medical Systems shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

DaVita has higher revenue and earnings than Merit Medical Systems. DaVita is trading at a lower price-to-earnings ratio than Merit Medical Systems, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DaVita	$13.64B	1.13	$746.80M	$10.78	22.26
Merit Medical Systems	$1.52B	3.35	$128.49M	$2.31	36.80

Summary

Merit Medical Systems beats DaVita on 11 of the 16 factors compared between the two stocks.

How does DaVita compare to Cardinal Health?

Cardinal Health (NYSE:CAH) and DaVita (NYSE:DVA) are both large-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, valuation, analyst recommendations, media sentiment and dividends.

DaVita has a net margin of 5.65% compared to Cardinal Health's net margin of 0.62%. Cardinal Health's return on equity of -92.61% beat DaVita's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardinal Health	0.62%	-92.61%	4.46%
DaVita	5.65%	-270.37%	4.87%

Cardinal Health currently has a consensus price target of $251.73, indicating a potential upside of 9.36%. DaVita has a consensus price target of $216.50, indicating a potential downside of 9.79%. Given Cardinal Health's stronger consensus rating and higher probable upside, equities analysts plainly believe Cardinal Health is more favorable than DaVita.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardinal Health	0 Sell rating(s)	3 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.83
DaVita	1 Sell rating(s)	5 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.13

Cardinal Health has a beta of 0.49, suggesting that its stock price is 51% less volatile than the broader market. Comparatively, DaVita has a beta of 0.88, suggesting that its stock price is 12% less volatile than the broader market.

In the previous week, Cardinal Health had 7 more articles in the media than DaVita. MarketBeat recorded 21 mentions for Cardinal Health and 14 mentions for DaVita. Cardinal Health's average media sentiment score of 1.35 beat DaVita's score of 1.08 indicating that Cardinal Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cardinal Health	19 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
DaVita	10 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

87.2% of Cardinal Health shares are owned by institutional investors. Comparatively, 90.1% of DaVita shares are owned by institutional investors. 0.1% of Cardinal Health shares are owned by insiders. Comparatively, 1.9% of DaVita shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Cardinal Health has higher revenue and earnings than DaVita. DaVita is trading at a lower price-to-earnings ratio than Cardinal Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardinal Health	$250.74B	0.22	$1.56B	$6.54	35.20
DaVita	$13.64B	1.13	$746.80M	$10.78	22.26

Summary

Cardinal Health beats DaVita on 9 of the 16 factors compared between the two stocks.

Get DaVita News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DVA vs. The Competition

Export

Metric	DaVita	Healthcare Providers & Services Industry	Healthcare Sector	NYSE Exchange
Market Cap	$15.33B	$9.96B	$7.24B	$23.71B
Dividend Yield	N/A	2.52%	2.59%	4.20%
P/E Ratio	22.26	25.49	280.89	31.01
Price / Sales	1.13	4.76	641.00	13.91
Price / Cash	11.00	125.44	71.02	31.71
Price / Book	-45.37	5.13	11.09	4.62
Net Income	$746.80M	$311.13M	$3.50B	$1.07B
7 Day Performance	1.93%	-0.29%	-0.25%	0.35%
1 Month Performance	5.41%	-0.52%	-2.98%	-0.19%
1 Year Performance	73.36%	26.17%	61.96%	19.11%

DaVita Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DVA DaVita	3.7986 of 5 stars	$240.00 +0.5%	$216.50 -9.8%	+71.1%	$15.33B	$13.64B	22.26	78,000	Positive News Upcoming Earnings
ALGN Align Technology	3.588 of 5 stars	$168.05 +0.6%	$206.36 +22.8%	+31.1%	$11.96B	$4.03B	28.20	20,290	Trending News Earnings Report Analyst Forecast
DXCM DexCom	3.755 of 5 stars	$73.37 +2.6%	$85.36 +16.3%	+3.3%	$27.61B	$4.66B	31.35	11,000	Trending News Earnings Report Analyst Forecast Insider Trade
HQY HealthEquity	4.0781 of 5 stars	$99.05 +4.7%	$110.93 +12.0%	+3.7%	$7.91B	$1.31B	37.10	2,814	Positive News
MMSI Merit Medical Systems	4.2161 of 5 stars	$76.10 +2.4%	$92.80 +21.9%	+0.2%	$4.43B	$1.52B	32.94	7,500	Trending News Earnings Report Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:DVA) was last updated on 8/1/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

DaVita (DVA) Competitors

DVA vs. ALGN, DXCM, HQY, MMSI, and CAH

How does DaVita compare to Align Technology?

Summary

How does DaVita compare to DexCom?

Summary

How does DaVita compare to HealthEquity?

Summary

How does DaVita compare to Merit Medical Systems?

Summary

How does DaVita compare to Cardinal Health?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DVA vs. The Competition

DaVita Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

DaVita (DVA) Competitors

DVA vs. ALGN, DXCM, HQY, MMSI, and CAH

How does DaVita compare to Align Technology?

Do analysts prefer DVA or ALGN?

Which has more volatility and risk, DVA or ALGN?

Do institutionals & insiders have more ownership in DVA or ALGN?

Is DVA or ALGN more profitable?

Does the media prefer DVA or ALGN?

Which has preferable valuation & earnings, DVA or ALGN?

Summary

How does DaVita compare to DexCom?

Which has higher valuation & earnings, DXCM or DVA?

Does the media prefer DXCM or DVA?

Is DXCM or DVA more profitable?

Which has more volatility and risk, DXCM or DVA?

Do analysts rate DXCM or DVA?

Do insiders & institutionals have more ownership in DXCM or DVA?

Summary

How does DaVita compare to HealthEquity?

Which has better earnings & valuation, DVA or HQY?

Does the media refer more to DVA or HQY?

Do insiders & institutionals believe in DVA or HQY?

Which has more risk & volatility, DVA or HQY?

Is DVA or HQY more profitable?

Do analysts prefer DVA or HQY?

Summary

How does DaVita compare to Merit Medical Systems?

Is DVA or MMSI more profitable?

Which has more risk & volatility, DVA or MMSI?

Do analysts prefer DVA or MMSI?

Does the media refer more to DVA or MMSI?

Do institutionals & insiders hold more shares of DVA or MMSI?

Which has preferable valuation & earnings, DVA or MMSI?

Summary

How does DaVita compare to Cardinal Health?

Is CAH or DVA more profitable?

Do analysts recommend CAH or DVA?

Which has more risk & volatility, CAH or DVA?

Does the media prefer CAH or DVA?

Do insiders and institutionals have more ownership in CAH or DVA?

Which has better earnings and valuation, CAH or DVA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DVA vs. The Competition

DaVita Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools